Occult primary, version 3.2014; Featured updates to the NCCN guidelines

David S. Ettinger, Charles R. Handorf, Mark Agulnik, Daniel W. Bowles, Justin M. Cates, Mihaela Cristea, Efrat Dotan, Keith D. Eaton, Panagiotis M. Fidias, David Gierada, G. Weldon Gilcrease, Kelly Godby, Renuka Iyer, Renato Lenzi, John Phay, Asif Rashid, Leonard Saltz, Richard B. Schwab, Lawrence N. Shulman, Jeffrey B. Smerage & 6 others Marvaretta M. Stevenson, Gauri R. Varadhachary, Jonathan S. Zager, Weining Zhen, Mary Anne Bergman, Deborah A. Freedman-Cass

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.

Original languageEnglish (US)
Pages (from-to)969-974
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume12
Issue number7
DOIs
StatePublished - Jul 1 2014

Fingerprint

Gene Expression Profiling
Unknown Primary Neoplasms
Guidelines
Neoplasms
Mutation
Therapeutics

ASJC Scopus subject areas

  • Oncology

Cite this

Ettinger, D. S., Handorf, C. R., Agulnik, M., Bowles, D. W., Cates, J. M., Cristea, M., ... Freedman-Cass, D. A. (2014). Occult primary, version 3.2014; Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 12(7), 969-974. https://doi.org/10.6004/jnccn.2014.0093

Occult primary, version 3.2014; Featured updates to the NCCN guidelines. / Ettinger, David S.; Handorf, Charles R.; Agulnik, Mark; Bowles, Daniel W.; Cates, Justin M.; Cristea, Mihaela; Dotan, Efrat; Eaton, Keith D.; Fidias, Panagiotis M.; Gierada, David; Weldon Gilcrease, G.; Godby, Kelly; Iyer, Renuka; Lenzi, Renato; Phay, John; Rashid, Asif; Saltz, Leonard; Schwab, Richard B.; Shulman, Lawrence N.; Smerage, Jeffrey B.; Stevenson, Marvaretta M.; Varadhachary, Gauri R.; Zager, Jonathan S.; Zhen, Weining; Bergman, Mary Anne; Freedman-Cass, Deborah A.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 12, No. 7, 01.07.2014, p. 969-974.

Research output: Contribution to journalArticle

Ettinger, DS, Handorf, CR, Agulnik, M, Bowles, DW, Cates, JM, Cristea, M, Dotan, E, Eaton, KD, Fidias, PM, Gierada, D, Weldon Gilcrease, G, Godby, K, Iyer, R, Lenzi, R, Phay, J, Rashid, A, Saltz, L, Schwab, RB, Shulman, LN, Smerage, JB, Stevenson, MM, Varadhachary, GR, Zager, JS, Zhen, W, Bergman, MA & Freedman-Cass, DA 2014, 'Occult primary, version 3.2014; Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 7, pp. 969-974. https://doi.org/10.6004/jnccn.2014.0093
Ettinger, David S. ; Handorf, Charles R. ; Agulnik, Mark ; Bowles, Daniel W. ; Cates, Justin M. ; Cristea, Mihaela ; Dotan, Efrat ; Eaton, Keith D. ; Fidias, Panagiotis M. ; Gierada, David ; Weldon Gilcrease, G. ; Godby, Kelly ; Iyer, Renuka ; Lenzi, Renato ; Phay, John ; Rashid, Asif ; Saltz, Leonard ; Schwab, Richard B. ; Shulman, Lawrence N. ; Smerage, Jeffrey B. ; Stevenson, Marvaretta M. ; Varadhachary, Gauri R. ; Zager, Jonathan S. ; Zhen, Weining ; Bergman, Mary Anne ; Freedman-Cass, Deborah A. / Occult primary, version 3.2014; Featured updates to the NCCN guidelines. In: JNCCN Journal of the National Comprehensive Cancer Network. 2014 ; Vol. 12, No. 7. pp. 969-974.
@article{05534441ee8443f88cce8db7b9145655,
title = "Occult primary, version 3.2014; Featured updates to the NCCN guidelines",
abstract = "The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20{\%} of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.",
author = "Ettinger, {David S.} and Handorf, {Charles R.} and Mark Agulnik and Bowles, {Daniel W.} and Cates, {Justin M.} and Mihaela Cristea and Efrat Dotan and Eaton, {Keith D.} and Fidias, {Panagiotis M.} and David Gierada and {Weldon Gilcrease}, G. and Kelly Godby and Renuka Iyer and Renato Lenzi and John Phay and Asif Rashid and Leonard Saltz and Schwab, {Richard B.} and Shulman, {Lawrence N.} and Smerage, {Jeffrey B.} and Stevenson, {Marvaretta M.} and Varadhachary, {Gauri R.} and Zager, {Jonathan S.} and Weining Zhen and Bergman, {Mary Anne} and Freedman-Cass, {Deborah A.}",
year = "2014",
month = "7",
day = "1",
doi = "10.6004/jnccn.2014.0093",
language = "English (US)",
volume = "12",
pages = "969--974",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "7",

}

TY - JOUR

T1 - Occult primary, version 3.2014; Featured updates to the NCCN guidelines

AU - Ettinger, David S.

AU - Handorf, Charles R.

AU - Agulnik, Mark

AU - Bowles, Daniel W.

AU - Cates, Justin M.

AU - Cristea, Mihaela

AU - Dotan, Efrat

AU - Eaton, Keith D.

AU - Fidias, Panagiotis M.

AU - Gierada, David

AU - Weldon Gilcrease, G.

AU - Godby, Kelly

AU - Iyer, Renuka

AU - Lenzi, Renato

AU - Phay, John

AU - Rashid, Asif

AU - Saltz, Leonard

AU - Schwab, Richard B.

AU - Shulman, Lawrence N.

AU - Smerage, Jeffrey B.

AU - Stevenson, Marvaretta M.

AU - Varadhachary, Gauri R.

AU - Zager, Jonathan S.

AU - Zhen, Weining

AU - Bergman, Mary Anne

AU - Freedman-Cass, Deborah A.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.

AB - The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion points of the 2014 NCCN Occult Primary panel meeting. The panel discussed gene expression profiling (GEP) for the identification of the tissue of origin and concluded that, although GEP has a diagnostic benefit, a clinical benefit has not been demonstrated. The panel recommends against GEP as standard management, although 20% of the panel believes the diagnostic benefit of GEP warrants its routine use. In addition, the panel discussed testing for actionable mutations (eg, ALK) to help guide choice of therapy, but declined to add this recommendation.

UR - http://www.scopus.com/inward/record.url?scp=84903965503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903965503&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0093

DO - 10.6004/jnccn.2014.0093

M3 - Article

VL - 12

SP - 969

EP - 974

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 7

ER -